012790 — Sinil Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeMicro CapContrarian

Annual income statement for Sinil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	61,754	80,007	89,135	89,440	80,564
Cost of Revenue
Gross Profit	24,441	35,645	37,570	40,666	33,437
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	53,758	66,443	75,151	74,188	73,070
Operating Profit	7,996	13,564	13,984	15,253	7,494
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	8,341	14,645	14,953	16,538	8,597
Provision for Income Taxes
Net Income After Taxes	6,679	12,157	13,641	14,301	7,531
Net Income Before Extraordinary Items
Net Income	6,679	12,157	13,641	14,301	7,531
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	6,679	12,157	13,641	14,301	7,531
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	592	1,083	1,231	1,235	645
Dividends per Share